Searched for: in-biosketch:true
person:segevd01
Mitigating the Disparate Impacts of Longevity Matching of Kidney Transplants [Editorial]
Gentry, Sommer E; Stewart, Darren E; Massie, Allan B; Segev, Dorry L
PMID: 38970578
ISSN: 1523-6838
CID: 5719172
Castleman disease patients report mild COVID-19 symptoms and mount a humoral response to SARS-CoV-2 vaccination
Shyamsundar, Saishravan; Pierson, Sheila K; Connolly, Caoilfhionn M; Teles, Mayan; Segev, Dorry L; Werbel, William A; van Rhee, Frits; Casper, Corey; Brandstadter, Joshua D; Noy, Ariela; Fajgenbaum, David C
The coronavirus disease of 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has resulted in increased morbidity and mortality in patients with impaired immunity, hematologic malignancies, and immunosuppressive regimens. COVID-19 can cause a cytokine storm with some patients benefiting from blockade of the pro-inflammatory cytokine, interleukin 6 (IL6). As Castleman disease (CD) is an atypical lymphoproliferative disorder that can involve a cytokine storm and often requires immunosuppressive therapies, including IL6 inhibition, we sought to evaluate outcomes following COVID-19 and SARS-CoV-2 vaccination in CD patients. We administered a survey in April 2021 to characterize experiences with COVID-19 and SARS-CoV-2 vaccination among 300 CD patients enrolled in ACCELERATE, a natural history registry of CD patients. Among 128 respondents, the prevalence of SARS-CoV-2 infection (16/95, 17%), severe disease (1/16, 6%), vaccination rates (112/128, 88%), and vaccine adverse effects after dose one (62/112, 55%) were comparable to the general U.S. population. While there were two cases of CD flares occurring shortly after SARS-CoV-2 infection (N=1) and vaccination (N=1), over 100 patients in this study that were infected and/or vaccinated did not experience CD flares. The median anti-spike titer six months after the second dose among CD patients was comparable to individuals with other immune-related diseases and healthy populations. Data from this small cohort suggest that, despite being on immunosuppressive therapies, CD patients do not appear to be at increased risk of poor COVID-19 outcomes and can mount a humoral response to SARS-CoV-2 vaccination. This study was registered on clinicaltrials.gov (#NCT02817997).
PMCID:11265787
PMID: 39044861
ISSN: 2950-3280
CID: 5723612
Diagnosing the Recent Decrease in Utilization of Deceased Donor Kidneys
Wood, Nicholas L; VanDerwerken, Douglas N; Massie, Allan B; Segev, Dorry L; Snyder, Jon J; Gentry, Sommer E
BACKGROUND:The number of deceased donor kidney transplants has been increasing and is at a record high, yet nonuse of kidneys recovered for transplantation has risen to 25.8% following circular kidney allocation system based on 250-nautical-mile circles implemented on March 15, 2021 (KAS250). METHODS:Using Scientific Registry of Transplant Recipients data, we studied all deceased donor kidneys recovered for transplant from March 15, 2019, to January 31, 2023. We calculated the association of multiple factors with kidney nonuse, including increasing recovery of kidneys from nonideal donors, delays in offer acceptance observed under KAS250, and impacts of COVID-19. RESULTS:In the 2 y before KAS250, the nonuse rate was 21.2%. Had this rate continued, 2334 more kidneys would have been transplanted through January 2023. We estimated that about 769 of these nonused kidneys (33%) were associated with offer acceptance delays under KAS250; about 994 of these nonused kidneys (43%) were associated with increased prevalence of nonideal donors: donation after circulatory death donors, older donors, and donors with elevated peak serum creatinine; and about 542 of these nonused kidneys (23%) were associated with an otherwise unexplained gradual upward trend in nonuse of recovered kidneys across the pre-KAS250 and KAS250 eras. The overall impact of COVID-19 on the nonuse rate was not significant. CONCLUSIONS:The rise in kidney nonuse rate was significantly associated with both increased recovery of nonideal donors, and with KAS250 allocation complexity and delays. Increasing recovery of kidneys from nonideal donors benefits patients because recovering more kidneys increases the number of kidneys available for transplant.
PMID: 39288350
ISSN: 1534-6080
CID: 5720462
A Metabolomics Approach to Identify Metabolites Associated With Mortality in Patients Receiving Maintenance Hemodialysis
Al Awadhi, Solaf; Myint, Leslie; Guallar, Eliseo; Clish, Clary B; Wulczyn, Kendra E; Kalim, Sahir; Thadhani, Ravi; Segev, Dorry L; McAdams DeMarco, Mara; Moe, Sharon M; Moorthi, Ranjani N; Hostetter, Thomas H; Himmelfarb, Jonathan; Meyer, Timothy W; Powe, Neil R; Tonelli, Marcello; Rhee, Eugene P; Shafi, Tariq
INTRODUCTION/UNASSIGNED:Uremic toxins contributing to increased risk of death remain largely unknown. We used untargeted metabolomics to identify plasma metabolites associated with mortality in patients receiving maintenance hemodialysis. METHODS/UNASSIGNED:We measured metabolites in serum samples from 522 Longitudinal US/Canada Incident Dialysis (LUCID) study participants. We assessed the association between metabolites and 1-year mortality, adjusting for age, sex, race, cardiovascular disease, diabetes, body mass index, serum albumin, Kt/Vurea, dialysis duration, and country. We modeled these associations using limma, a metabolite-wise linear model with empirical Bayesian inference, and 2 machine learning (ML) models: Least absolute shrinkage and selection operator (LASSO) and random forest (RF). We accounted for multiple testing using a false discovery rate (pFDR) adjustment. We defined significant mortality-metabolite associations as pFDR < 0.1 in the limma model and metabolites of at least medium importance in both ML models. RESULTS/UNASSIGNED:limma. CONCLUSION/UNASSIGNED:Quinolinate and mesaconate were significantly associated with a 1-year risk of death in incident patients receiving maintenance hemodialysis. External validation of our findings is needed.
PMCID:11403082
PMID: 39291216
ISSN: 2468-0249
CID: 5720942
National Attitudes Toward Living Kidney Donation in the United States: Results of a Public Opinion Survey
Kaplow, Katya; Ruck, Jessica M; Levan, Macey L; Thomas, Alvin G; Stewart, Darren; Massie, Allan B; Sung, Hannah C; Pisano, Sarah F; Sidoti, Carolyn; Segev, Dorry L; Sinacore, Joseph; Waterman, Amy D
RATIONALE & OBJECTIVE/UNASSIGNED:Understanding national attitudes about living kidney donation will enable us to identify and address existing disincentives to living kidney donation. We performed a national survey to describe living kidney donation perceptions, perceived factors that affect the willingness to donate, and analyzed differences by demographic subgroups. STUDY DESIGN/UNASSIGNED:The survey items captured living kidney donation awareness, living kidney donation knowledge, willingness to donate, and barriers and facilitators to living kidney donation. SETTING & POPULATION/UNASSIGNED:We surveyed 802 US adults (aged 25-65 years) in June 2021, randomly selected from an online platform with diverse representation. ANALYTICAL APPROACH/UNASSIGNED:and Fisher exact tests. We inductively evaluated free-text responses to identify additional barriers and facilitators to living kidney donation. RESULTS/UNASSIGNED:Most (86.6%) of the respondents reported that they might or would definitely consider donating a kidney while they were still living. Barriers to living kidney donation included concerns about the risk of the surgery, paying for medical expenses, and potential health effects. Facilitators to living kidney donation included having information on the donation surgery's safety, knowing that the donor would not have to pay for medical expenses related to the donation, and hearing living kidney donation success stories. Awareness of the ability to participate in kidney-paired donation was associated with a higher willingness to donate. LIMITATIONS/UNASSIGNED:Potential for selection bias resulting from the use of survey panels and varied incentive amounts, and measurement error related to respondents' attention level. CONCLUSIONS/UNASSIGNED:Most people would consider becoming a living kidney donor. Increased rates of living kidney donation may be possible with investment in culturally competent educational interventions that address risks associated with donating, policies that reduce financial disincentives, and communication campaigns that raise awareness of kidney-paired donation and living kidney donation.
PMCID:10906424
PMID: 38435064
ISSN: 2590-0595
CID: 5723042
A Delphi Panel Study for Public Education about Vascularized Composite Allograft Donation in the United States
Downey, Max C; Sidoti, Carolyn N; Ferzola, Alexander; Anderson, Naomi; Sung, Hannah C; Van Pilsum Rasmussen, Sarah E; Vanterpool, Karen B; Segev, Dorry L; Cooney, Carisa M; Kimberly, Laura L; Warren, Daniel S; Johnson, Ieesha D; Brandacher, Gerald; Gordon, Elisa J; Levan, Macey L
PMID: 39095046
ISSN: 2164-6708
CID: 5713992
Rapid Wane and Recovery of XBB Sublineage Neutralization After Sequential Omicron-based Vaccination in Solid Organ Transplant Recipients
Johnston, Trevor S; Hage, Camille; Abedon, Aura T; Panda, Snigdha; Alejo, Jennifer L; Eby, Yolanda; Segev, Dorry L; Tobian, Aaron A R; Cox, Andrea L; Werbel, William A; Karaba, Andrew H
Durability of variant neutralization in solid organ transplant recipients following Omicron-containing boosters is unknown. We report wane in XBB.1.5 neutralization by 3 months following a first bivalent booster, improved by a second booster; hybrid immunity improved peak, and duration of neutralization. Boosting at 3 to 6 months appears necessary to maintain neutralization.
PMCID:11426267
PMID: 38953683
ISSN: 1537-6591
CID: 5713902
ChatGPT Solving Complex Kidney Transplant Cases: A Comparative Study With Human Respondents
Mankowski, Michal A; Jaffe, Ian S; Xu, Jingzhi; Bae, Sunjae; Oermann, Eric K; Aphinyanaphongs, Yindalon; McAdams-DeMarco, Mara A; Lonze, Bonnie E; Orandi, Babak J; Stewart, Darren; Levan, Macey; Massie, Allan; Gentry, Sommer; Segev, Dorry L
INTRODUCTION/BACKGROUND:ChatGPT has shown the ability to answer clinical questions in general medicine but may be constrained by the specialized nature of kidney transplantation. Thus, it is important to explore how ChatGPT can be used in kidney transplantation and how its knowledge compares to human respondents. METHODS:We prompted ChatGPT versions 3.5, 4, and 4 Visual (4 V) with 12 multiple-choice questions related to six kidney transplant cases from 2013 to 2015 American Society of Nephrology (ASN) fellowship program quizzes. We compared the performance of ChatGPT with US nephrology fellowship program directors, nephrology fellows, and the audience of the ASN's annual Kidney Week meeting. RESULTS:Overall, ChatGPT 4 V correctly answered 10 out of 12 questions, showing a performance level comparable to nephrology fellows (group majority correctly answered 9 of 12 questions) and training program directors (11 of 12). This surpassed ChatGPT 4 (7 of 12 correct) and 3.5 (5 of 12). All three ChatGPT versions failed to correctly answer questions where the consensus among human respondents was low. CONCLUSION/CONCLUSIONS:Each iterative version of ChatGPT performed better than the prior version, with version 4 V achieving performance on par with nephrology fellows and training program directors. While it shows promise in understanding and answering kidney transplantation questions, ChatGPT should be seen as a complementary tool to human expertise rather than a replacement.
PMCID:11441623
PMID: 39329220
ISSN: 1399-0012
CID: 5714092
Safety of Kidney Transplantation from Donors with HIV
Durand, Christine M; Massie, Allan; Florman, Sander; Liang, Tao; Rana, Meenakshi M; Friedman-Moraco, Rachel; Gilbert, Alexander; Stock, Peter; Mehta, Sapna A; Mehta, Shikha; Stosor, Valentina; Pereira, Marcus R; Morris, Michele I; Hand, Jonathan; Aslam, Saima; Malinis, Maricar; Haidar, Ghady; Small, Catherine B; Santos, Carlos A Q; Schaenman, Joanna; Baddley, John; Wojciechowski, David; Blumberg, Emily A; Ranganna, Karthik; Adebiyi, Oluwafisayo; Elias, Nahel; Castillo-Lugo, Jose A; Giorgakis, Emmanouil; Apewokin, Senu; Brown, Diane; Ostrander, Darin; Eby, Yolanda; Desai, Niraj; Naqvi, Fizza; Bagnasco, Serena; Watson, Natasha; Brittain, Erica; Odim, Jonah; Redd, Andrew D; Tobian, Aaron A R; Segev, Dorry L; ,
BACKGROUND:Kidney transplantation from donors with human immunodeficiency virus (HIV) to recipients with HIV is an emerging practice. It has been performed since 2016 under the U.S. congressional HIV Organ Policy Equity Act and is currently approved for research only. The Department of Health and Human Services is considering expanding the procedure to clinical practice, but data are limited to small case series that did not include donors without HIV as controls. METHODS:In an observational study conducted at 26 U.S. centers, we compared transplantation of kidneys from deceased donors with HIV and donors without HIV to recipients with HIV. The primary outcome was a safety event (a composite of death from any cause, graft loss, serious adverse event, HIV breakthrough infection, persistent failure of HIV treatment, or opportunistic infection), assessed for noninferiority (margin for the upper bound of the 95% confidence interval, 3.00). Secondary outcomes included overall survival, survival without graft loss, rejection, infection, cancer, and HIV superinfection. RESULTS:We enrolled 408 transplantation candidates, of whom 198 received a kidney from a deceased donor; 99 received a kidney from a donor with HIV and 99 from a donor without HIV. The adjusted hazard ratio for the composite primary outcome was 1.00 (95% confidence interval [CI], 0.73 to 1.38), which showed noninferiority. The following secondary outcomes were similar whether the donor had HIV or not: overall survival at 1 year (94% vs. 95%) and 3 years (85% vs. 87%), survival without graft loss at 1 year (93% vs. 90%) and 3 years (84% vs. 81%), and rejection at 1 year (13% vs. 21%) and 3 years (21% vs. 24%). The incidence of serious adverse events, infections, surgical or vascular complications, and cancer was similar in the groups. The incidence of HIV breakthrough infection was higher among recipients of kidneys from donors with HIV (incidence rate ratio, 3.14; 95%, CI, 1.02 to 9.63), with one potential HIV superinfection among the 58 recipients in this group with sequence data and no persistent failures of HIV treatment. CONCLUSIONS:In this observational study of kidney transplantation in persons with HIV, transplantation from donors with HIV appeared to be noninferior to that from donors without HIV. (Funded by the National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov number, NCT03500315.).
PMID: 39413376
ISSN: 1533-4406
CID: 5711682
Thirty-Year Trends in Perioperative Mortality Risk for Living Kidney Donors
Massie, Allan B; Motter, Jennifer D; Snyder, Jon J; Levan, Macey L; Segev, Dorry L
PMID: 39196582
ISSN: 1538-3598
CID: 5711412